Cytek Biosciences Inc
NASDAQ:CTKB

Watchlist Manager
Cytek Biosciences Inc Logo
Cytek Biosciences Inc
NASDAQ:CTKB
Watchlist
Price: 4.63 USD 1.31% Market Closed
Market Cap: $595.2m

Cytek Biosciences Inc
Total Liabilities & Equity

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Cytek Biosciences Inc
Total Liabilities & Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
Cytek Biosciences Inc
NASDAQ:CTKB
Total Liabilities & Equity
$461.5m
CAGR 3-Years
-4%
CAGR 5-Years
16%
CAGR 10-Years
N/A
Thermo Fisher Scientific Inc
NYSE:TMO
Total Liabilities & Equity
$110.3B
CAGR 3-Years
4%
CAGR 5-Years
10%
CAGR 10-Years
10%
Danaher Corp
NYSE:DHR
Total Liabilities & Equity
$83.5B
CAGR 3-Years
0%
CAGR 5-Years
2%
CAGR 10-Years
6%
Waters Corp
NYSE:WAT
Total Liabilities & Equity
$5.1B
CAGR 3-Years
16%
CAGR 5-Years
12%
CAGR 10-Years
2%
Agilent Technologies Inc
NYSE:A
Total Liabilities & Equity
$12.8B
CAGR 3-Years
5%
CAGR 5-Years
6%
CAGR 10-Years
6%
IQVIA Holdings Inc
NYSE:IQV
Total Liabilities & Equity
$29.9B
CAGR 3-Years
6%
CAGR 5-Years
4%
CAGR 10-Years
23%
No Stocks Found

Cytek Biosciences Inc
Glance View

Cytek Biosciences, Inc. is a life sciences technology company engages in the provision of cell analysis tools by leveraging novel technical approaches. The company is headquartered in Fremont, California and currently employs 496 full-time employees. The company went IPO on 2021-07-23. The firm offers cell analysis tools by leveraging technical approaches. Its instruments, the Aurora and Northern Lights systems, are the spectrum flow cytometers able to deliver cell analysis by utilizing the spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells Full Spectrum Profiling (FSP). The Company’s FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize a method of light detection and distribution. Its FSP platform includes instruments, reagents, software and services to provide an integrated suite of solutions for its customers. The firm has sold and deployed over 1,000 instruments, primarily comprised of its Aurora and Northern Lights systems to customers around the world, including the pharmaceutical companies, over 150 biopharma companies, academic research centers, and clinical research organizations (CROs).

CTKB Intrinsic Value
4.08 USD
Overvaluation 12%
Intrinsic Value
Price $4.63

See Also

What is Cytek Biosciences Inc's Total Liabilities & Equity?
Total Liabilities & Equity
461.5m USD

Based on the financial report for Dec 31, 2025, Cytek Biosciences Inc's Total Liabilities & Equity amounts to 461.5m USD.

What is Cytek Biosciences Inc's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
16%

Over the last year, the Total Liabilities & Equity growth was -8%. The average annual Total Liabilities & Equity growth rates for Cytek Biosciences Inc have been -4% over the past three years , 16% over the past five years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett